EKOS™ Endovascular System

The most studied device in the space.

With 14 clinical trials published, EKOSTM Endovascular System offers years of proven success.

Visit our Venous Thromboembolism portal
Sign-Up for Product Updates

Real world. Real answers. REAL-PE.

The REAL-PE Analysis is the largest real-world and near real-time dataset evaluating advanced therapies for PE patients.
View the results

Pulmonary Embolism

The EKOS™ Endovascular System is the most studied device in the pulmonary embolism space. Since 2014, several major studies have demonstrated clinically significant results in quality of life scores1, mortality2, and long-term safety and efficacy1,3,4 for acute, massive (high risk) and submassive (intermediate risk) PE.

  • EKOS brings 23-26% reduction to the RV/LV ratio – without an increase in bleeding1, 3,4
  • It allows for lower lytic doses – up to 88-92% less than for standard systemic treatment – and shorter delivery duration of the thrombolytic agent5,1
  • It enables shorter average length of hospital stay (3.2 days)than for patients being treated with anticoagulation alone (6.7 days)6

Access full clinical overview of EKOS ultrasound-assisted thrombolysis for Pulmonary Embolism.

View full details on related EKOSTM clinical studies

Deep Vein Thrombosis

The EKOSTM Endovascular System quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS).

  • Up to 50% of DVT patients have PE7
  • Removes thrombus more completely compared to CDT8
  • Reduces post-thrombotic syndrome9
In the ACCESS PTS study, 73 patients with chronic DVT treated with a regimen of both balloon dilatation and EKOSTM therapy saw a significant reduction in Villalta Score of 49% and a 36% improvement in VEINS-QOL at one year.10

Completed studies on EKOS™ for DVT are:

CAVA: A randomised controlled multicenter trial comparing ultrasound-accelerated catheter-directed thrombolysis, combined with standard anticoagulant therapy, with standard anticoagulant therapy alone, for acute primary iliofemoral deep vein thrombosis (Level 1) A.

ACCESS PTS: ACCElerated ThrombolySiS for Post-Thrombotic Syndrome Using the EKOS™ System (Level 2) Chronicdvtstudy.com

Arterial Occlusion

The EKOSTM Endovascular System improves on standard CDT by safely accelerating drug penetration, even in difficult-to-reach areas:

  • Shorter treatment times11
  • Lower 30-day amputation rate11
  • Lower bleeding rates when compared to CDT11
  • Higher complete dissolution rate of thrombus11
  • Shorter hospital stays11

Completed trials on EKOSTM for PAO are: 

DUET: Dutch randomised trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thrombo-embolic infra-inguinal.

Top